A Systems Approach for Tumor Pharmacokinetics
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Recent advances in genome inspired target discovery, small molecule screens, development of biological and nanotechnology have led to the introduction of a myriad of new differently sized agents into the clinic. The differences in small and large molecule delivery are becoming increasingly important in combination therapies as well as the use of drugs that modify the physiology of tumors such as anti-angiogenic treatment. The complexity of targeting has led to the development of mathematical models to facilitate understanding, but unfortunately, these studies are often only applicable to a particular molecule, making pharmacokinetic comparisons difficult. Here we develop and describe a framework for categorizing primary pharmacokinetics of drugs in tumors. For modeling purposes, we define drugs not by their mechanism of action but rather their rate-limiting step of delivery. Our simulations account for variations in perfusion, vascularization, interstitial transport, and non-linear local binding and metabolism. Based on a comparison of the fundamental rates determining uptake, drugs were classified into four categories depending on whether uptake is limited by blood flow, extravasation, interstitial diffusion, or local binding and metabolism. Simulations comparing small molecule versus macromolecular drugs show a sharp difference in distribution, which has implications for multi-drug therapies. The tissue-level distribution differs widely in tumors for small molecules versus macromolecular biologic drugs, and this should be considered in the design of agents and treatments. An example using antibodies in mouse xenografts illustrates the different in vivo behavior. This type of transport analysis can be used to aid in model development, experimental data analysis, and imaging and therapeutic agent design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Therapies such as bevacizumab and other antiangiogenic treatments ‘normalize’ tumor blood vessels by reducing permeability, increasing pericytes coverage, and restoring pressure gradients [53].”
BackgroundDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Despite its importance, poor drug distribution and overall tumoral uptake is often neglected as a mechanism of drug resistance in cancer [1] and becomes even more complicated in multidrug regimens [2].”
BackgroundCell and environment interactions in tumor microregions: the multicell spheroid model.
Sutherland, R. M. (1988) · Science · doi:10.1126/science.2451290 · Cited by 1,803 · cited 1×
“Agents that have direct access to the tissue avoid the blood flow and endothelial barriers but often have long diffusion distances within the target tissue [29,30].”
BackgroundHecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Next-Generation Model-Based Drug Discovery and Development: Quantitative and Systems Pharmacology
Allerheiligen, S. R. B. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.81 · Cited by 56
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Quorum-sensing Salmonella selectively trigger protein expression within tumors
Swofford, C. A., Van Dessel, N., & Forbes, N. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414558112 · Cited by 145
A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
Vasalou, C., Helmlinger, G., & Gomes, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118977 · Cited by 98
Bartelink, I. H., Jones, E. F., Shahidi‐Latham, S. K., Lee, P. R. E., Zheng, Y., Vicini, P., van ‘t Veer, L., Wolf, D., Iagaru, A., Kroetz, D. L., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1211 · Cited by 96
“Tumor tissue penetration is largely determined by a variety of factors in the tumor microenvironment.(25) This includes tumor vascular architecture, the composition and structure of the extracellular matrix, and the stroma.”
Background
Metadata
- Authors
- Thurber, G. M., & Weissleder, R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-09-14
- Volume
- 6
- Issue
- 9
- Pages
- e24696
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2084478449
- Cited by
- 130
- References
- 5
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systems Approach for Tumor Pharmacokinetics. https://app.cochat.ai/papers/10.1371/journal.pone.0024696
- The paper
- Thurber, G. M., & Weissleder, R. (2011). A Systems Approach for Tumor Pharmacokinetics. PLoS ONE. https://doi.org/10.1371/journal.pone.0024696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.